[Long-Term Survival of a Patient with KRAS Mutated Colon Cancer Successfully Treated with Regorafenib].
A 65-year-old woman underwent iliocecal resection for cecal cancer. During post-operative follow-up, she was diagnosed with metastasis to the abdominal wall and a curative resection was performed. After 12 courses of adjuvant chemotherapy with a modified combination of folinic acid, 5-fluorouracil, and oxaliplatin (mFOLFOX6), recurrence was noted in the lung. A curative resection was successfully performed and she was subsequently treated with bevacizumab and a combination of folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI). One year after surgical resection, recurrence in the remnant lung was diagnosed. Because of the KRAS mutation, she could not be treated with anti-epidermal growth factor antibodies. The metastatic lung tumor continued to enlarge. Therefore, we selected regorafenib as third-line chemotherapy. After treatment with regorafenib, the size of the target lesion decreased significantly.
Dept. of Surgery, Institute of Gastroenterology, Kawasaki Saiwai Hospital.
Ryo
R
Ohta
Koji
K
Sekikawa
Masato
M
Yamazaki
Manabu
M
Goto
Kazuhiro
K
Narita
Hironari
H
Ikeda
Masataka
M
Oneyama
Mikihiro
M
Nakayama
Yota
Y
Shimoda
Shun
S
Sato
Takahiro
T
Inoue
D000368:Aged; D002430:Cecal Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009154:Mutation; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D011725:Pyridines / Q000627:therapeutic use*; D012008:Recurrence; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D018631:ras Proteins / Q000235:genetics*
C117307:KRAS protein, human; D010671:Phenylurea Compounds; D011518:Proto-Oncogene Proteins; D011725:Pyridines; C559147:regorafenib; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins